Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Aurobindo Expects To Be In Top Three For Immunology Biosimilar - Is It Xolair?

Pneumococcal Vaccine Filing In H2

Jun 07 2022

• By Vibha Ravi

Clinical Research Image — Aurobindo Is Making Progress In Biosimilars' Development • Source: Shutterstock

Related Content

It’s Deal Time: Aurobindo on M&A, Divestment Path

Feb 11 2022

Selexis And Generium Launch Omalizumab Biosimilar In Russia

Feb 10 2022

Russia Sanctions, China Lockdown To Pinch Globally With Higher Freight, API Costs

Apr 06 2022

COVID-19 Relapses, Lack Of Omicron Data Complicate Paxlovid Case In India

May 13 2022

Strides Founder Back As MD, Asserts Confidence In US As Company Exits Parts Of Europe

Jun 02 2022

Related Companies

Aurobindo Pharma Limited

Novartis AG

Roche Holding AG

Amgen, Inc.

Additional Topics

India Asia Pacific Research & Development Biosimilars Sales & Earnings Business Strategies BioPharmaceutical

More from R&D

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.